SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Pre-treatment quality of life and survival outcomes in lung cancer patients: a systematic review and meta-analysis.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a leading cause of cancer-related mortality, with baseline (pre-treatment) quality of life (QOL) increasingly recognized as a potential prognostic factor for survival. This systematic review and meta-analysis evaluates the association between baseline (pre-treatment) QOL and mortality in lung cancer patients.
methodsFollowing PRISMA guidelines and PROSPERO registration (CRD42023398206), we searched PubMed/MEDLINE, Web of Science, and Scopus up to July 2025 for observational studies examining baseline (pre-treatment) QOL and survival in lung cancer patients. Eligible studies used validated QOL tools and reported hazard ratios (HRs) for mortality. Data were extracted independently by two reviewers, and study quality was assessed using the Newcastle-Ottawa Scale. Random-effects meta-analyses quantified associations between global and domain-specific QOL (physical, emotional, cognitive, social) and mortality, with heterogeneity assessed via I
resultsThirty-nine studies (n = 20,235 patients) across 18 countries were included. Lower baseline (pre-treatment) global QoL was associated with increased mortality risk (pooled HR = 1.07; 95% CI: 1.02-1.12), with similar associations observed for physical, emotional, and social QoL domains. Cognitive QoL (HR = 0.99; 95% CI: 0.97-1.00) and FACT-G/FACT-L scores (HR = 0.94; 95% CI: 0.80-1.09) showed no significant association. Substantial heterogeneity (I
conclusionsLower baseline QoL is associated with increased mortality risk, indicating that higher QoL is protective and associated with improved survival. Standardized methodologies are needed to address heterogeneity and enhance evidence quality. Findings may vary by disease stage; stage-stratified estimates were rarely reported.
Indexed as
Identifiers
42240738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.